Gund pledges $50 million for blindness research

Businessman and philanthropist Gordon Gund is pledging $50 million in matching donations as part of an effort to restore vision for some blind people.

Gund is chairman of the Foundation Fighting Blindness, based in Columbia, Maryland. The 74-year-old former owner of the Cleveland Cavaliers lost his sight to a degenerative retinal disease at age 30.

On Saturday, the foundation announced that Gund will match $50 million or more in contributions to fund research to cure retinal diseases that cause blindness. The goal is to raise $100 million total by 2020.

Gund says the foundation has already made significant advances toward its and that the funding will help maintain its momentum. Research from the foundation helped lead to the commercial launch of the first "bionic retina."

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Grape-enriched diet supports eye health

May 29, 2014

New research presented this week at the Association for Research in Vision and Ophthalmology conference in Orlando, Florida suggests that regular grape consumption may play a role in eye health by protecting the retina from ...

Recommended for you

Why aren't there any human doctors in Star Wars?

Jan 30, 2015

Though set "a long time ago in a galaxy far, far away," it isn't hard to see in the Star Wars films a vision of our own not so distant future. But Anthony Jones, a physician with a long background in health ...

Cambodia bans 'virgin surgery' adverts

Jan 29, 2015

The Cambodian government has ordered a hospital to stop advertising so-called virginity restoration procedures, saying it harms the "morality" of society.

What's happening with your donated specimen?

Jan 28, 2015

When donating blood, plasma, human tissue or any other bodily sample for medical research, most people might not think about how it's being used. But if you were told, would you care?

Amgen tops Street 4Q forecasts

Jan 27, 2015

Amgen Inc. cruised to a 27 percent jump in fourth-quarter profit and beat Wall Street expectations, due to higher sales of nearly all its medicines, tight cost controls and a tax benefit.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.